Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA) (NCT06698250)
Phase II Trial of Zanzalintinib (XL-092) in Combination With Durvalumab Plus Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)
๐ฉบ Plain-English Summary (8th-Grade Level)
This study will investigate if modulating the tumor microenvironment with biologic agents like XL-092 will have synergistic e๏ฌect when combined with checkpoint based immunotherapeutic treatment of patients with hepatocellular carcinoma (HCC).
Who can join: Review the eligibility criteria below.
Location: UPMC Hillman Cancer Center โ Pittsburgh, Pennsylvania
Age range: 18 Years
๐งช Interventions in This Study
๐ "Do I Qualify?" โ 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria โ
๐ All Participating Trial Locations (3 Sites)
- UPMC Hillman Cancer Center โ Pittsburgh, Pennsylvania
- Houston Methodist Neal Cancer Center โ Houston, Texas
- Mays Cancer Center, UT Health San Antonio โ San Antonio, Texas
๐ Contact the Study Coordinator
Phone: (412) 623-8364
Email: diecksda@upmc.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
๐ฐ Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA ยง 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Hepatocellular Carcinoma
- TACE With or Without SBRT as Bridging Therapy for Pre-transplant HCC Patients โ Maywood, Illinois
- Cryoablation and Arterial Infusion of SD-101 in Combination With Durvalumab and Tremelimumab โ San Diego, California
- Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC) โ Baltimore, Maryland
- TheraSphere With Durvalumab and Tremelimumab for HCC โ San Diego, California
- Blood Salvage in Orthotopic Liver Transplantation With HCC โ Toronto, Ontario
- Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC) โ Prescott Valley, Arizona
Explore by condition: All Hepatocellular Carcinoma clinical trials
๐ก How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.